Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study of its benmelstobart injection at the 2025 American Society of Clinical Oncology Annual Meeting, a Thursday Hong Kong bourse filing said.
The drug is being studied for use with or without anlotinib hydrochloride capsules as maintenance treatment for non-small cell lung cancer without progression following chemoradiotherapy.
The median progression-free survival of the arm of benmelstobart in combination with anlotinib was significantly prolonged with a 51% lower risk of disease progression or death, compared with the arm of the placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.